JP2009545595A5 - - Google Patents

Download PDF

Info

Publication number
JP2009545595A5
JP2009545595A5 JP2009522861A JP2009522861A JP2009545595A5 JP 2009545595 A5 JP2009545595 A5 JP 2009545595A5 JP 2009522861 A JP2009522861 A JP 2009522861A JP 2009522861 A JP2009522861 A JP 2009522861A JP 2009545595 A5 JP2009545595 A5 JP 2009545595A5
Authority
JP
Japan
Prior art keywords
composition
poloxamer
heart failure
item
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009522861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009545595A (ja
JP5537152B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017182 external-priority patent/WO2008016640A2/en
Publication of JP2009545595A publication Critical patent/JP2009545595A/ja
Publication of JP2009545595A5 publication Critical patent/JP2009545595A5/ja
Application granted granted Critical
Publication of JP5537152B2 publication Critical patent/JP5537152B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009522861A 2006-08-01 2007-08-01 慢性進行性心不全のための処置 Expired - Fee Related JP5537152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83472806P 2006-08-01 2006-08-01
US60/834,728 2006-08-01
PCT/US2007/017182 WO2008016640A2 (en) 2006-08-01 2007-08-01 Use of poloxamer for the prevention and/or treatment of heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013189091A Division JP2013253103A (ja) 2006-08-01 2013-09-12 慢性進行性心不全のための処置

Publications (3)

Publication Number Publication Date
JP2009545595A JP2009545595A (ja) 2009-12-24
JP2009545595A5 true JP2009545595A5 (enExample) 2011-09-29
JP5537152B2 JP5537152B2 (ja) 2014-07-02

Family

ID=38805633

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009522861A Expired - Fee Related JP5537152B2 (ja) 2006-08-01 2007-08-01 慢性進行性心不全のための処置
JP2013189091A Withdrawn JP2013253103A (ja) 2006-08-01 2013-09-12 慢性進行性心不全のための処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013189091A Withdrawn JP2013253103A (ja) 2006-08-01 2013-09-12 慢性進行性心不全のための処置

Country Status (7)

Country Link
US (1) US9155758B2 (enExample)
EP (1) EP2046348B1 (enExample)
JP (2) JP5537152B2 (enExample)
CN (4) CN101534843A (enExample)
AU (1) AU2007281531B2 (enExample)
CA (1) CA2659909A1 (enExample)
WO (1) WO2008016640A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5537152B2 (ja) 2006-08-01 2014-07-02 フリクサス ファーマシューティカルズ, インコーポレイテッド 慢性進行性心不全のための処置
CA2682234A1 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2011156389A2 (en) * 2010-06-07 2011-12-15 The Regents Of The University Of California The islet amyloid polypeptide toxic oligomer is a biomarker of heart or kidney failure in type-2 diabetes mellitus
US20160235781A1 (en) * 2013-10-16 2016-08-18 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
TWI688392B (zh) 2014-07-07 2020-03-21 美商救生筏生物科技公司 無長循環材料之泊洛沙姆組成物以及其製造方法和用途
WO2016007542A1 (en) * 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US20230190676A1 (en) * 2020-07-09 2023-06-22 Musc Foundation For Research Development Methods of protecting cells from insults
CN111973623B (zh) * 2020-08-06 2022-04-05 温州医科大学 心力衰竭靶向治疗的速释制剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198211A (en) 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0576612B1 (en) 1991-03-19 1999-12-01 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
JPH05178760A (ja) 1991-06-03 1993-07-20 Alpha Therapeutic Corp 心筋梗塞治療剤
US5605687A (en) 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
WO2000021543A1 (en) 1998-10-09 2000-04-20 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
WO2002065834A2 (en) 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US7341552B2 (en) 2002-03-15 2008-03-11 The University Of Texas System Board Of Regents Gene sets for glioma classification
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
WO2006037031A2 (en) 2004-09-27 2006-04-06 Valentis, Inc. Formulations and methods for treatment of inflammatory diseases
EP1809272A4 (en) 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
CA2599219C (en) 2005-02-25 2011-09-20 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
PT1861080E (pt) 2005-03-21 2010-06-17 Santhera Pharmaceuticals Ch Derivado de quinona 2,3-dimetoxi-5-metil-6-(10- hidroxidecil)-1,4-benzoquinona para o tratamento de distrofias musculares
DK1978947T3 (da) 2006-02-03 2014-11-03 Nicox Science Ireland Nitrooxyderivater til anvendelse ved behandling af muskeldystrofier
JP5537152B2 (ja) 2006-08-01 2014-07-02 フリクサス ファーマシューティカルズ, インコーポレイテッド 慢性進行性心不全のための処置
CA2682234A1 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009078978A2 (en) 2007-12-14 2009-06-25 Phrixus Pharmaceuticals, Inc. Compositions containing polyglycidol-based polymers and uses thereof
EP2719389B1 (en) 2007-12-17 2016-07-06 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
WO2011066201A2 (en) 2009-11-25 2011-06-03 The Regents Of The University Of Michigan Methods and systems for treating and preventing cardiac injury in dystrophic subjects

Similar Documents

Publication Publication Date Title
Kasama et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction
US6894024B2 (en) Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
Thompson et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
Hidalgo et al. Effect of exercise training on post-translational and post-transcriptional regulation of titin stiffness in striated muscle of wild type and IG KO mice
DK2683393T3 (en) TRIPEPTIME COMPOSITIONS AND THEIR USE IN TREATING DIABETES
KR20200111822A (ko) 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제
JP2015506942A5 (enExample)
CA2966756A1 (en) Methods of treating ckd using predictors of fluid retention
Sezer et al. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support
US10004754B2 (en) ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment
Choi et al. Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry
TW202245792A (zh) 靜脈注射伊司他星用於治療急性心臟衰竭
CN103402534B (zh) 用于治疗充血性心力衰竭的治疗方法
CN111317811B (zh) 短胜肽用于治疗或预防高血压及其相关疾病的用途
TW202313021A (zh) 作為強心劑之六氫吡啶脲衍生物
EP3072521A1 (en) Use of recombined ganoderma lucidum immunoregulation protein (rlz-8) in preparing drugs for treating tissue fibrosis
US20250235502A1 (en) Cardio-protective effect of vasoconstriction-inhibiting factor (vif)
WO2013102921A2 (en) Hcg - newer treatment modality for type 2 diabetes mellitus (t2dm)
WO2016133069A1 (ja) 心不全の予防又は治療のための医薬
Liakos et al. Canagliflozin for type 2 diabetes: an up-to-date evidence summary
Erdoğan et al. Sinus tachycardia related to tacrolimus after kidney transplantation in children and young adults
Doumas et al. Left Ventricular Structure and Clinical Characteristics of Non-Dilated Cardiomyopathy
EA047888B1 (ru) Применение производных пиперидин мочевины в качестве инотропных агентов
Li et al. Hypertension Management
Accadia et al. Apical ballooning-like syndrome: Hypocalcemia? What else!